Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) known for its analgesic, anti-inflammatory, and antipyretic properties [1]. It functions by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of prostaglandins, which are key mediators in pain, inflammation, and fever [2]. Commonly used to treat conditions such as headache, dysmenorrhea, arthritis, and fever, ibuprofen is available in multiple formulations including tablets, capsules, oral suspensions, and topical gels [3]. Despite its over-the-counter availability in many countries, including Brazil under the oversight of ANVISA, it carries risks such as gastrointestinal bleeding, renal impairment, and increased cardiovascular risk, particularly with long-term or high-dose use [4]. Its pharmacokinetics involve rapid gastrointestinal absorption, hepatic metabolism via cytochrome P450 enzymes (mainly CYP2C9), and renal excretion, with a short half-life of about 2 hours [5]. Special precautions are necessary in vulnerable populations such as elderly patients and those with pre-existing hypertension or chronic kidney disease. The drug also interacts significantly with other medications, including warfarin and diuretics, increasing the risk of adverse events [6]. Overdose can lead to severe toxicity, including metabolic acidosis and acute kidney injury, requiring prompt emergency management [7].

Pharmacological Classification and Mechanism of Action

Ibuprofen is classified as a nonsteroidal anti-inflammatory drug (NSAID), a pharmacological group characterized by its ability to reduce pain, inflammation, and fever [1]. Its therapeutic effects stem from the inhibition of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which play a central role in the biosynthesis of prostaglandins, key mediators in inflammatory and nociceptive processes [2].

Pharmacological Classification

Ibuprofen belongs to the chemical class of derivatives of phenylacetic acid and is categorized within the ATC (Anatomical Therapeutic Chemical) classification system under the code M01AE01, which identifies it as a non-selective NSAID [1]. It is considered a reversible, non-selective inhibitor of both COX-1 and COX-2 isoforms, meaning it binds competitively to the active site of these enzymes and does not permanently inactivate them [11]. This non-selectivity differentiates it from COX-2 selective inhibitors like celecoxib, which were developed to minimize gastrointestinal toxicity. The drug's pharmacological profile supports its use as an analgesic, anti-inflammatory, and antipyretic agent, making it a cornerstone in the management of various acute and chronic conditions [12].

Mechanism of Action

The primary mechanism of action of ibuprofen involves the inhibition of the COX enzymes, which catalyze the conversion of arachidonic acid into prostaglandin H2 (PGH2), the precursor for a cascade of bioactive prostaglandins and thromboxanes [13]. COX-1 is constitutively expressed in most tissues and is responsible for maintaining physiological functions, including the protection of the gastric mucosa, regulation of renal blood flow, and platelet aggregation via thromboxane A2 production [14]. In contrast, COX-2 is primarily induced at sites of inflammation by cytokines and tissue injury, leading to the production of prostaglandins such as PGE2, which mediate pain, swelling, and fever [14].

By inhibiting both COX isoforms, ibuprofen effectively reduces the synthesis of prostaglandins, thereby producing its therapeutic effects. The anti-inflammatory action is achieved by decreasing the levels of PGE2, which reduces vasodilation, vascular permeability, and the recruitment of inflammatory cells to the site of injury [16]. The analgesic effect results from the diminished sensitization of peripheral nociceptors to painful stimuli, as prostaglandins lower the threshold for pain perception [17]. For its antipyretic effect, ibuprofen acts on the hypothalamic thermoregulatory center, where the inhibition of COX-2 reduces the production of PGE2, which is responsible for resetting the body's temperature set-point during fever [17]. This central action helps normalize body temperature in febrile states.

Consequences of COX Inhibition

While the inhibition of COX-2 is primarily responsible for the desired therapeutic effects, the concurrent inhibition of COX-1 underlies many of the drug's adverse effects. The reduction of gastroprotective prostaglandins, such as PGI2 and PGE2, compromises the integrity of the gastric mucosa by decreasing mucus and bicarbonate secretion and reducing mucosal blood flow, thereby increasing the risk of gastritis, peptic ulcers, and gastrointestinal bleeding [19]. Similarly, in the kidneys, prostaglandins play a crucial role in maintaining glomerular filtration rate (GFR), particularly in states of reduced effective circulating volume. Inhibition of renal prostaglandin synthesis can lead to vasoconstriction of the afferent arteriole, resulting in decreased renal perfusion, fluid retention, and, in severe cases, acute kidney injury, especially in vulnerable populations [20]. Furthermore, the inhibition of COX-1 in platelets reduces thromboxane A2 production, leading to a transient impairment of platelet aggregation, which differentiates it from the irreversible effect of aspirin [21].

Medical Uses and Clinical Indications

Ibuprofen is a widely used nonsteroidal anti-inflammatory drug (NSAID) with well-established clinical applications due to its analgesic, anti-inflammatory, and antipyretic properties [1]. It is indicated for the management of a variety of acute and chronic conditions involving pain, inflammation, and fever, making it a cornerstone in both over-the-counter (OTC) and prescription-based treatment regimens.

Pain Relief

Ibuprofen is highly effective in alleviating mild to moderate pain of diverse origins. Its analgesic action is particularly beneficial in conditions where inflammation contributes to pain generation. Common indications include headache, dental pain, muscle pain, back pain, and dysmenorrhea (menstrual cramps) [23]. The drug's ability to inhibit prostaglandin synthesis reduces peripheral sensitization of nociceptors, thereby decreasing pain perception. It is also used for postoperative pain and pain associated with sprains, strains, and contusions, where its anti-inflammatory effect contributes to functional recovery [24].

Inflammatory Conditions

The anti-inflammatory properties of ibuprofen make it a key therapeutic agent in managing chronic inflammatory disorders, particularly those affecting the musculoskeletal system. It is commonly prescribed for the symptomatic treatment of osteoarthritis and rheumatoid arthritis, helping to reduce joint pain, stiffness, and swelling [25]. In these conditions, ibuprofen is often used as an adjunct to disease-modifying antirheumatic drugs (DMARDs) to control inflammatory symptoms. It is also effective in treating other inflammatory joint diseases and soft tissue conditions such as tendinitis and bursitis.

Fever Reduction

As an antipyretic, ibuprofen is used to reduce elevated body temperature in conditions such as the common cold, influenza, and other infections [4]. It acts by inhibiting prostaglandin E2 (PGE2) synthesis in the hypothalamus, the brain's temperature-regulating center, thereby resetting the body's thermostat to a normal level. Its antipyretic efficacy is comparable to, and sometimes superior to, paracetamol, particularly in cases with a significant inflammatory component [27].

Symptomatic Management of Cold and Flu

Ibuprofen is frequently included in the symptomatic management of upper respiratory tract infections. It helps alleviate a combination of symptoms associated with colds and flu, including sore throat, body aches, headache, and fever [28]. Its multi-symptom relief profile makes it a popular choice for OTC cold and flu medications, although it does not treat the underlying viral infection.

Use in Special Populations and Clinical Decision-Making

The choice of ibuprofen as a first-line treatment depends on the clinical context and patient factors. Compared to other NSAIDs like diclofenac or naproxen, ibuprofen is often preferred for mild to moderate pain due to its relatively favorable safety profile, especially at lower doses [29]. In pediatrics, it is indicated for children over 6 months of age for fever and pain, with dosing carefully adjusted to body weight [30]. In geriatric patients, while effective, its use requires caution due to increased risks of gastrointestinal bleeding, renal impairment, and cardiovascular events, necessitating the use of the lowest effective dose for the shortest duration possible [31]. For patients with hypertension or a history of gastrointestinal issues, alternatives like paracetamol are often recommended as a safer first choice [32].

Dosage and Administration by Age Group

The appropriate dosage and administration of ibuprofen vary significantly based on the patient's age, weight, and clinical condition. Accurate dosing is essential to ensure therapeutic efficacy while minimizing the risk of adverse effects, particularly in vulnerable populations such as infants, children, and the elderly. The principles of pharmacokinetics, including rapid gastrointestinal absorption, short half-life (approximately 2 hours), and hepatic metabolism via cytochrome P450 enzymes (mainly CYP2C9), underpin the dosing regimens across age groups [5]. Dosing adjustments are necessary to account for developmental and physiological differences in drug handling.

Adults and Adolescents (≥12 years)

For adults and adolescents aged 12 years and older, ibuprofen is typically administered orally in the form of tablets, capsules, or oral suspensions. The standard dose ranges from 200 mg to 400 mg, taken every 4 to 6 hours as needed for pain or fever relief [5]. In some cases, under medical supervision, the dose can be increased to 600 mg or 800 mg per administration, particularly for inflammatory conditions like arthritis [35]. The maximum daily dose for over-the-counter use is 1200 mg, but under medical guidance, it can be increased to 3200 mg per day, divided into 3 or 4 doses [36]. To minimize the risk of gastrointestinal bleeding, it is recommended to take the medication with food or milk [37].

Children (6 months to 11 years)

In children, ibuprofen dosing must be calculated based on body weight to ensure safety and efficacy. It is indicated for use in children 6 months of age and older [38]. The recommended dose is 5 to 10 mg per kilogram of body weight per dose, administered every 6 to 8 hours, with a maximum of 4 doses in 24 hours [39]. The total daily dose should not exceed 30 to 40 mg/kg [40]. For example, a child weighing 10 kg may receive 50 to 100 mg per dose.

Pediatric formulations, such as oral suspensions (e.g., 20 mg/mL or 50 mg/mL) and drops (e.g., 100 mg/mL), are designed to facilitate accurate dosing [41]. It is crucial to use the calibrated dropper or oral syringe provided with the product to avoid dosing errors [42]. Before administration, the suspension should be shaken well to ensure uniform distribution of the active ingredient. The use of ibuprofen in children under 6 months is contraindicated unless under strict medical supervision [43].

Infants (Under 6 months)

Ibuprofen is not recommended for use in infants younger than 6 months of age unless specifically prescribed by a physician [38]. The immature renal and hepatic systems in this age group increase the risk of adverse effects, including renal impairment and metabolic disturbances. In cases where analgesia or antipyresis is needed, alternatives such as paracetamol are preferred due to a more favorable safety profile in this population [27]. Any use of ibuprofen in this age group must be based on a careful risk-benefit assessment by a pediatrician.

Elderly Patients

In elderly patients, the use of ibuprofen requires special caution due to age-related physiological changes, including decreased renal function and reduced hepatic metabolism [31]. Although the pharmacokinetics of ibuprofen are not significantly altered in the elderly, the risk of adverse effects—particularly gastrointestinal bleeding, renal impairment, and cardiovascular events—is substantially higher [47]. Therefore, the lowest effective dose should be used for the shortest duration possible. Doses of 200 to 400 mg every 6 to 8 hours are generally recommended, with close monitoring of renal and hepatic function. Concomitant use of anticoagulants, diuretics, or ACE inhibitors further increases the risk of complications and should be avoided or carefully managed [6].

Special Considerations for Administration

The route of administration depends on the pharmaceutical form and patient needs. Oral administration is the most common, but topical gels (containing 50 mg/g) can be applied 3 to 4 times daily to affected areas for localized pain, such as muscle strains or sprains [49]. Rectal formulations, though less common, are available for specific indications like hemorrhoids [50]. Regardless of the form, adherence to recommended dosing intervals and maximum daily limits is critical to prevent toxicity and ensure safe use across all age groups.

Pharmaceutical Forms and Bioavailability

Ibuprofen is available in a variety of pharmaceutical forms, each designed to optimize delivery, patient compliance, and therapeutic outcomes across different populations and clinical scenarios. The choice of formulation significantly influences the drug's bioavailability, onset of action, and systemic exposure, allowing for tailored treatment strategies in both acute and chronic conditions. These forms include oral, topical, and rectal preparations, each with distinct pharmacokinetic profiles and clinical applications.

Oral Formulations

Oral administration is the most common route for ibuprofen, offering rapid and reliable absorption. The primary oral forms include tablets, capsules, oral suspensions, and oral drops, each suited to specific age groups and dosing requirements.

  • Tablets and Capsules: Standard oral tablets, often film-coated, are available in strengths of 400 mg and 600 mg and are intended for adults and adolescents aged 12 years and older [51]. These are typically administered with water, preferably during or after meals to minimize gastric irritation [37]. Capsules, including soft gelatin capsules, offer similar dosing and are also used in adults [53]. Both forms exhibit high gastrointestinal absorption, with peak plasma concentrations achieved within 1 to 2 hours [5].

  • Oral Suspensions and Drops: These liquid formulations are primarily used in pediatric populations, especially children over 6 months of age [41]. Suspensions are commonly available at concentrations of 20 mg/mL, 50 mg/mL, or 100 mg/mL, allowing for precise dose adjustments based on the child's weight [40]. Administration is facilitated by graduated syringes or droppers, ensuring accuracy and ease of use [42]. These formulations are rapidly absorbed, with bioavailability comparable to solid oral forms, and are particularly effective for managing fever and mild to moderate pain in children [39].

  • Modified-Release Tablets: Extended-release (ER) or prolonged-release formulations are engineered to provide sustained plasma levels over 8 to 12 hours, reducing dosing frequency and improving adherence in chronic conditions such as osteoarthritis or rheumatoid arthritis [59]. These systems utilize polymer matrices or other controlled-release technologies to modulate drug release, maintaining therapeutic efficacy while minimizing peak concentration-related adverse effects [60].

Topical Formulations

Topical forms of ibuprofen, such as gels and creams, are designed for localized treatment of musculoskeletal pain, including muscle strain, sprain, and tendinitis. The most common concentration is 50 mg/g, applied directly to the affected area 3 to 4 times daily with gentle massage [49].

The key advantage of topical administration is the reduction of systemic exposure, which significantly lowers the risk of gastrointestinal bleeding and other systemic adverse effects associated with oral NSAIDs [62]. Despite limited systemic absorption—estimated to be 5 to 17 times lower than oral forms—topical ibuprofen achieves therapeutic concentrations in underlying tissues, making it an effective option for localized inflammation and pain [63]. Advanced delivery systems, such as liposomes and nanocarriers, are being explored to enhance skin penetration and tissue retention [64].

Rectal Formulation

Although less commonly used, a rectal ointment containing ibuprofen (50 + 10 mg/g) is available for the treatment of hemorrhoids, anal fissures, and pruritus ani, as regulated by ANVISA [50]. This formulation allows for local anti-inflammatory and analgesic effects with minimal systemic absorption, making it suitable for patients who cannot tolerate oral NSAIDs.

Bioavailability and Pharmacokinetic Influences

The bioavailability of ibuprofen varies depending on the formulation and route of administration. Oral forms generally exhibit high bioavailability (80–90%) due to efficient absorption in the small intestine [66]. The presence of food may slightly delay the time to peak concentration but does not significantly affect overall absorption, allowing for flexible dosing [5].

In contrast, topical formulations result in significantly lower systemic levels, which is beneficial for minimizing risks in patients with chronic kidney disease or hypertension. However, this also limits their use to localized conditions rather than systemic inflammation or high-grade fever.

Innovative delivery systems, such as self-emulsifying drug delivery systems (SEDDS), have been developed to enhance the solubility and absorption of ibuprofen, particularly in patients with impaired gastrointestinal function [68]. These systems improve bioavailability by promoting micelle formation in the gut, facilitating passive diffusion across the intestinal membrane.

Quality Control and Stability

The stability of ibuprofen formulations is rigorously monitored to ensure potency and safety throughout the product's shelf life. Regulatory agencies such as ANVISA and the European Medicines Agency (EMA) require comprehensive stability testing under accelerated and long-term storage conditions [69]. Factors such as temperature, humidity, and light exposure are controlled to prevent degradation, with recommended storage in cool, dry places away from direct sunlight [70]. For suspensions, proper agitation before use is essential to maintain uniformity and ensure accurate dosing [71].

Adverse Effects and Safety Profile

Ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), is generally well tolerated when used at recommended doses and for short durations. However, its use is associated with a range of adverse effects, particularly with long-term use, high doses, or in vulnerable populations. The safety profile of ibuprofen is primarily shaped by its mechanism of action—nonselective inhibition of cyclooxygenase (COX) enzymes—which affects not only inflammatory pathways but also physiological processes involving prostaglandins in the gastrointestinal, renal, and cardiovascular systems [2].

Gastrointestinal Adverse Effects

The most common adverse effects of ibuprofen are related to the gastrointestinal (GI) tract. By inhibiting COX-1, ibuprofen reduces the synthesis of gastroprotective prostaglandins such as PGE2 and PGI2, which are essential for maintaining mucosal integrity, promoting mucus and bicarbonate secretion, and regulating mucosal blood flow [73]. This disruption increases the risk of GI complications, including:

  • Dyspepsia, heartburn, and abdominal pain
  • Gastritis, peptic ulcers, and gastrointestinal bleeding
  • Perforation or obstruction of the digestive tract, particularly in severe cases [2]

These risks are significantly elevated in patients with a history of peptic ulcer disease, those taking concomitant medications such as corticosteroids or anticoagulants, and in elderly individuals, who are more susceptible due to age-related declines in mucosal defense mechanisms [75]. The use of gastroprotective agents, such as proton pump inhibitors (PPIs), is often recommended in high-risk patients to mitigate these effects [76].

Cardiovascular Risks

Ibuprofen use is associated with an increased risk of serious cardiovascular events, including myocardial infarction, stroke, and cardiac arrest. A recent study found that ibuprofen use increases the risk of cardiac arrest by 31%, highlighting a significant cardiovascular safety concern [77]. The risk is dose-dependent, with daily doses of 2400 mg or higher posing a greater threat, although even doses above 1200 mg/day may contribute to elevated cardiovascular risk [29].

The mechanism involves an imbalance between vasoconstrictive, pro-thrombotic thromboxane A2 (derived from platelets) and vasodilatory, anti-aggregatory prostacyclin (derived from endothelial cells). By inhibiting COX-1 and COX-2, ibuprofen disrupts this balance, favoring thrombosis and vasoconstriction. This risk is particularly pronounced in patients with pre-existing cardiovascular disease, hypertension, or other cardiovascular risk factors [29].

Renal Adverse Effects

Ibuprofen can cause both acute and chronic kidney injury, especially in patients with pre-existing renal impairment, dehydration, heart failure, or cirrhosis. Prostaglandins such as PGE2 and PGI2 play a crucial role in maintaining renal perfusion by promoting vasodilation of afferent arterioles. Inhibiting their synthesis can lead to renal vasoconstriction, reduced glomerular filtration rate (GFR), and acute kidney injury [80].

Chronic use may result in more severe complications, including interstitial nephritis, papillary necrosis, and progressive chronic kidney disease. The risk is heightened in elderly patients and those taking diuretics or angiotensin-converting enzyme inhibitors (ACE inhibitors), which further compromise renal perfusion [81]. Regular monitoring of renal function is advised for patients on long-term ibuprofen therapy.

Other Common and Rare Adverse Effects

In addition to the major organ system risks, ibuprofen may cause a variety of other adverse effects:

  • Neurological symptoms: Headache, dizziness, somnolence, and confusion are frequently reported. Tinnitus (ringing in the ears) can occur, particularly in overdose [7].
  • Cutaneous reactions: Skin rashes, pruritus, and erythema are common. Rare but severe reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and angioedema [83].
  • Hepatic effects: Although less common, ibuprofen can cause elevated liver enzymes and, in rare cases, hepatotoxicity. This risk may be increased with high doses or prolonged use [84].
  • Taste disturbances: Some patients report a metallic taste in the mouth, a less common but documented side effect [2].

Safety in Special Populations

Elderly Patients

The elderly are at increased risk of adverse effects due to age-related declines in renal and hepatic function, higher prevalence of comorbidities, and polypharmacy. The risk of GI bleeding, renal impairment, and cardiovascular events is significantly higher in this population. Therefore, the lowest effective dose for the shortest duration is recommended, and concomitant use of gastroprotective agents should be considered [86].

Pediatric Patients

In children over 6 months of age, ibuprofen is generally safe when dosed according to weight (5–10 mg/kg per dose). However, caution is required in dehydrated children, as this increases the risk of acute kidney injury. Pediatric formulations, such as oral suspensions, are designed for accurate dosing and improved palatability to enhance adherence [30].

Patients with Comorbidities

Ibuprofen is contraindicated or requires extreme caution in patients with:

  • Active peptic ulcer disease or history of GI bleeding
  • Severe heart, liver, or kidney failure
  • Hypertension, especially if poorly controlled
  • Asthma or allergic reactions to aspirin or other NSAIDs [88]

Risk Management and Prevention

To minimize adverse effects, several strategies are recommended:

  • Use the lowest effective dose for the shortest possible duration
  • Avoid concomitant use of other NSAIDs, corticosteroids, or anticoagulants unless absolutely necessary
  • Prefer alternative analgesics like paracetamol in high-risk patients
  • Educate patients about warning signs of serious adverse effects, such as black stools, abdominal pain, swelling, or reduced urine output
  • Monitor blood pressure, renal function, and liver enzymes in patients on long-term therapy [29]

In summary, while ibuprofen is a valuable and effective medication for pain, inflammation, and fever, its use must be balanced against a well-defined safety profile. Awareness of its potential adverse effects—particularly gastrointestinal, cardiovascular, and renal—is essential for safe prescribing and patient counseling.

Contraindications and Drug Interactions

The use of ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), is associated with several contraindications and clinically significant drug interactions that must be carefully considered to ensure patient safety. These risks are particularly pronounced in individuals with pre-existing conditions or those taking concomitant medications, necessitating a thorough evaluation before initiating therapy.

Absolute and Relative Contraindications

Ibuprofen is contraindicated in several clinical scenarios where the risk of serious adverse events outweighs potential therapeutic benefits. Absolute contraindications include hypersensitivity to ibuprofen or other NSAIDs, which can manifest as severe allergic reactions such as asthma, urticaria, rhinitis, angioedema, or bronchospasm [88]. Patients with a history of active peptic ulcer disease, gastrointestinal bleeding, or perforation related to previous NSAID use should not receive ibuprofen due to the high risk of recurrence [88]. Additionally, ibuprofen is contraindicated in patients with severe heart failure, advanced liver disease, or significant renal impairment, as it may exacerbate these conditions [92]. The use of ibuprofen is also strictly contraindicated during the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus and other complications [88].

Relative contraindications require cautious use and often involve dose adjustments or protective measures. These include conditions such as hypertension, where ibuprofen can interfere with the efficacy of antihypertensive agents and increase cardiovascular risk, particularly at high doses (≥2400 mg/day) [94]. Patients with a history of gastrointestinal disorders, such as gastritis or previous ulcers, are at increased risk of complications and may benefit from concomitant gastroprotective therapy, such as proton pump inhibitors [95]. Similarly, individuals with chronic kidney disease are more susceptible to acute kidney injury due to reduced renal perfusion caused by inhibition of vasodilatory prostaglandins [2].

Major Drug Interactions

Ibuprofen interacts with a variety of medications, increasing the risk of adverse outcomes. One of the most critical interactions is with anticoagulants, particularly warfarin. The combination significantly elevates the risk of gastrointestinal and systemic bleeding due to dual effects: ibuprofen's inhibition of platelet aggregation via COX-1 and its irritant effect on the gastric mucosa [6]. This interaction can also potentiate warfarin’s anticoagulant effect, leading to elevated International Normalized Ratio (INR) levels and an increased likelihood of hemorrhagic events [98]. Therefore, concurrent use should be avoided whenever possible, and if necessary, close monitoring of INR and clinical signs of bleeding is essential [99].

Interactions with diuretics and antihypertensive agents are also clinically significant. Ibuprofen can diminish the effectiveness of diuretics such as furosemide and thiazides by inhibiting renal prostaglandin synthesis, which plays a key role in maintaining renal blood flow, especially in volume-depleted states [100]. This can lead to sodium and water retention, worsening hypertension, and potentially precipitating acute kidney injury [101]. Similarly, ibuprofen may reduce the antihypertensive effects of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), beta-blockers, and diuretics, thereby compromising blood pressure control [29]. Regular monitoring of blood pressure and renal function is recommended when ibuprofen is used in patients with hypertension [103].

Concomitant use of ibuprofen with other NSAIDs is not recommended due to an additive increase in gastrointestinal toxicity, including ulceration and bleeding, without providing additional therapeutic benefit [104]. The cumulative inhibition of COX enzymes heightens the risk of renal impairment, heart failure exacerbation, and systemic toxicity [105]. Patients should be advised against combining over-the-counter NSAIDs, including those found in multi-symptom cold and flu preparations [106].

Special Considerations in High-Risk Populations

Elderly patients and those with multiple comorbidities are particularly vulnerable to the adverse effects of ibuprofen and its interactions. Age-related declines in renal and hepatic function reduce the body's ability to metabolize and eliminate the drug, increasing the risk of accumulation and toxicity [31]. The use of polypharmacy in this population further amplifies interaction risks, especially with medications affecting the cardiovascular and renal systems [108]. In patients with diabetes or pre-existing cardiovascular disease, ibuprofen may increase the risk of myocardial infarction and stroke, particularly with prolonged or high-dose use [29].

To minimize risks, healthcare providers should prioritize alternative analgesics such as acetaminophen (paracetamol), which has a more favorable safety profile in these populations [27]. When ibuprofen is necessary, the lowest effective dose should be used for the shortest duration possible, with regular monitoring of renal function, blood pressure, and signs of gastrointestinal bleeding [111]. Patient education on recognizing warning signs—such as abdominal pain, coffee-ground vomitus, melena, edema, or decreased urine output—is crucial for early intervention [112]. Ultimately, individualized risk-benefit assessment and adherence to prescribing guidelines are essential for the safe use of ibuprofen in complex clinical scenarios.

Use in Special Populations

The use of ibuprofen requires careful consideration in special populations due to altered pharmacokinetics, increased susceptibility to adverse effects, and the presence of comorbidities that can amplify risks. These populations include pediatrics, geriatrics, and individuals with pre-existing conditions such as hypertension, chronic kidney disease, or cardiovascular disease. The balance between therapeutic benefit and potential harm must be carefully evaluated, and dosing should be individualized based on risk factors and clinical status.

Pediatrics

Ibuprofen is approved for use in children aged 6 months and older, primarily for the management of fever and mild to moderate pain, including dysmenorrhea and musculoskeletal discomfort [30]. Its efficacy in reducing fever is well established, with studies showing it to be comparable or superior to paracetamol in certain contexts [27]. However, its use in children requires strict adherence to weight-based dosing to prevent overdose and toxicity.

The recommended dose for pediatric patients is 5 to 10 mg/kg per dose, administered every 6 to 8 hours, with a maximum daily dose of 40 mg/kg [42]. Administration should be done using calibrated devices such as oral syringes to ensure accuracy. Despite its widespread use, caution is advised in children under 2 years of age due to the immaturity of metabolic and excretory systems, which can increase the risk of hepatotoxicity and nephrotoxicity [43]. In cases of dehydration, such as during febrile illness, the risk of acute kidney injury is significantly elevated due to reduced renal perfusion and the drug's inhibition of vasodilatory prostaglandins [117].

Geriatrics

Elderly patients are at increased risk of adverse effects from ibuprofen due to age-related physiological changes, including reduced glomerular filtration rate and hepatic function, which impair drug clearance [73]. The risk of serious gastrointestinal complications, such as gastrointestinal bleeding and peptic ulceration, is up to five times higher in older adults compared to younger individuals [47]. This is primarily due to the inhibition of COX-1, which reduces the production of gastroprotective prostaglandins.

Additionally, elderly patients often have multiple comorbidities and are on polypharmacy regimens, increasing the potential for drug interactions. Concurrent use with anticoagulants such as warfarin significantly elevates the risk of hemorrhage [108]. Similarly, interactions with diuretics, ACE inhibitors, and beta-blockers can compromise renal function and blood pressure control [29]. Given these risks, the lowest effective dose should be used for the shortest duration possible, and alternative analgesics such as paracetamol are often preferred [31].

Patients with Comorbidities

The use of ibuprofen in patients with chronic conditions requires special precautions due to the potential for exacerbating underlying diseases.

In patients with hypertension, ibuprofen can interfere with the effectiveness of antihypertensive medications, particularly ACE inhibitors, angiotensin receptor blockers (ARBs), and diuretics. This occurs through the inhibition of renal prostaglandins, which play a role in maintaining renal blood flow and sodium excretion. The resulting fluid retention and vasoconstriction can lead to elevated blood pressure and increased cardiovascular risk [123]. Doses exceeding 2400 mg/day are associated with a significantly higher risk of myocardial infarction and stroke [94].

For patients with gastrointestinal disorders, particularly those with a history of peptic ulcer disease or gastrointestinal bleeding, ibuprofen is contraindicated due to its ulcerogenic potential [88]. In high-risk patients, co-therapy with a proton pump inhibitor may be necessary to reduce the risk of mucosal injury [76].

In renal impairment, ibuprofen can precipitate acute kidney injury by reducing glomerular filtration rate, especially in volume-depleted states. It is contraindicated in severe renal dysfunction and should be avoided in patients with chronic kidney disease, particularly if they are dehydrated or on concomitant nephrotoxic agents [127]. Regular monitoring of renal function is essential during prolonged therapy.

Pregnancy and Lactation

Ibuprofen is contraindicated during the third trimester of pregnancy due to the risk of premature closure of the ductus arteriosus, which can lead to fetal pulmonary hypertension and other complications [88]. Its use in the first and second trimesters should be limited to the lowest effective dose and shortest duration, only when clearly needed. In lactation, ibuprofen is considered relatively safe, as only small amounts are excreted in breast milk, but caution is still advised, particularly with long-term use [129].

Regulatory Oversight and Post-Marketing Surveillance

The regulatory oversight and post-marketing surveillance of ibuprofen involve a coordinated framework managed by national and international health authorities to ensure its safety, efficacy, and quality after approval and widespread use. In countries where ibuprofen is available over-the-counter (OTC), such as Brazil and Portugal, regulatory agencies implement strict controls on its sale, labeling, and monitoring of adverse events. These systems are designed to detect, evaluate, and prevent risks associated with its use, particularly in vulnerable populations and in cases of long-term or high-dose administration.

Regulatory Framework in Brazil and Portugal

In Brazil, the Agência Nacional de Vigilância Sanitária (ANVISA) is responsible for regulating the sale and distribution of ibuprofen. The agency classifies ibuprofen as a medication exempt from prescription (MIP), allowing OTC access in pharmacies and drugstores [130]. This classification is based on its established safety profile for short-term use in mild to moderate pain and fever. However, ANVISA maintains active oversight due to risks associated with inappropriate self-medication, such as gastrointestinal bleeding, renal impairment, and increased cardiovascular risk, especially in conditions like dengue, where ibuprofen may exacerbate hemorrhagic complications [131]. The agency also enforces compliance with good manufacturing practices and conducts periodic safety reviews.

In Portugal, the INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde) regulates ibuprofen under the European Union’s harmonized framework. While ibuprofen is available OTC, INFARMED imposes restrictions on the quantity sold per transaction and mandates pharmacist counseling to ensure appropriate use [132]. This approach reflects broader EU concerns about the cardiovascular and gastrointestinal risks of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly at high doses. The European Medicines Agency (EMA) has issued warnings that daily doses of 2400 mg or more are associated with a small but significant increase in the risk of serious cardiovascular events, such as myocardial infarction [133]. These findings influence national policies and labeling requirements across member states.

Labeling and Consumer Information Requirements

Labeling standards for ibuprofen are strictly regulated to ensure consumer safety and informed use. In Brazil, ANVISA’s Resolution RDC No. 768/2022 mandates clear and standardized labeling on all ibuprofen products [134]. Required information includes the generic name, concentration, dosage instructions, contraindications, and prominent warnings about gastrointestinal, cardiovascular, and renal risks. The label must also include instructions to consult a healthcare professional if symptoms persist beyond three days for fever or ten days for pain, reinforcing the need for medical evaluation in prolonged cases.

Similarly, in Portugal, labeling follows EU directives enforced by INFARMED, requiring information in Portuguese on indications, contraindications (e.g., active peptic ulcer, severe renal failure), and specific warnings for high-risk groups [135]. Labels must emphasize not exceeding the recommended dose and avoiding concomitant use with other NSAIDs or anticoagulants like warfarin. These measures aim to reduce the risk of adverse drug interactions and promote responsible self-medication.

Post-Marketing Surveillance and Pharmacovigilance

Post-marketing surveillance is a critical component of ibuprofen regulation, ensuring ongoing monitoring of its safety profile after widespread use. In Brazil, ANVISA operates a national pharmacovigilance system under Resolution RDC No. 16/2007, which requires healthcare professionals and manufacturers to report adverse events [136]. The agency analyzes these reports to identify emerging safety signals, such as increased incidence of acute kidney injury or gastrointestinal hemorrhage, particularly in elderly patients or those with pre-existing conditions like hypertension or chronic kidney disease. ANVISA also issues periodic safety bulletins and public alerts to inform healthcare providers and the public.

In Portugal, INFARMED participates in the EudraVigilance system, the European Union’s centralized database for adverse drug reaction reporting [137]. This allows real-time monitoring of ibuprofen-related events across Europe, facilitating rapid responses to safety concerns. For instance, alerts have been issued discouraging ibuprofen use in viral infections such as dengue, Zika, or chikungunya due to the potential for hemorrhagic complications. Patients and professionals are encouraged to report adverse events through INFARMED’s online portal, contributing to a robust post-marketing surveillance network.

Challenges in Harmonizing Regulatory Standards Across Lusophone Countries

Regulatory differences between Brazil, Portugal, and other Portuguese-speaking countries pose challenges for the uniform registration and commercialization of ibuprofen products. While Brazil and Portugal have well-established regulatory systems, other lusophone nations, such as Angola, face limitations in regulatory infrastructure, leading to potential gaps in quality control and pharmacovigilance [138]. These disparities can affect the consistency of product quality, labeling accuracy, and the ability to respond to safety signals. Manufacturers seeking to market ibuprofen in multiple lusophone countries must navigate varying requirements for dosing limits, packaging, and post-marketing reporting, often necessitating product-specific adaptations.

Despite these challenges, there is a growing trend toward harmonization, particularly through alignment with international standards such as those of the International Council for Harmonisation (ICH) and the World Health Organization (WHO). This facilitates the development of high-quality, safe, and effective ibuprofen formulations across diverse markets. Continuous collaboration between regulatory agencies, healthcare providers, and pharmaceutical companies is essential to ensure that post-marketing surveillance remains effective and responsive to evolving safety data.

Toxicity and Overdose Management

Overdose of ibuprofen, a widely used nonsteroidal anti-inflammatory drug (NSAID), can lead to severe and potentially life-threatening complications. Prompt recognition and management are essential to prevent irreversible organ damage or death. The clinical presentation and treatment approach vary based on the dose ingested, time since ingestion, and the patient’s baseline health status [7].

Clinical Signs and Symptoms of Acute Ibuprofen Toxicity

The clinical course of ibuprofen overdose evolves over the first 24 hours, progressing from mild gastrointestinal and neurological symptoms to severe systemic complications. The timeline and severity depend on the ingested dose, formulation (e.g., extended-release), and individual risk factors such as age and comorbidities.

Early Phase (0–4 Hours Post-Ingestion)

Within the first few hours, patients typically present with gastrointestinal and mild neurological symptoms due to direct irritation and early systemic absorption. Common signs include:

  • Nausea and vomiting, often accompanied by abdominal pain and diarrhea [140].
  • Headache, dizziness, and somnolence, resulting from the drug’s effect on the central nervous system (CNS) [7].
  • Tinnitus (ringing in the ears), an early sign of toxicity, particularly with high-dose ingestion [7].

These symptoms usually appear within 4 hours and indicate active gastrointestinal absorption.

Intermediate Phase (4–12 Hours Post-Ingestion)

Between 4 and 12 hours, the initial symptoms may worsen, and systemic complications begin to emerge. Key developments include:

  • Worsening gastrointestinal distress, with risk of acute gastritis, peptic ulceration, or gastrointestinal hemorrhage, manifesting as coffee-ground emesis or melena [112].
  • Altered mental status, such as confusion, agitation, or decreased level of consciousness, signaling more significant CNS involvement [7].
  • Autonomic instability, including hypersalivation and palpitations, reflecting toxicity to the autonomic nervous system [140].

This phase is critical for intervention, as delayed treatment increases the risk of irreversible damage.

Late Phase (12–24 Hours Post-Ingestion)

After 12 hours, even patients who were initially asymptomatic may develop severe, life-threatening complications:

  • Metabolic acidosis, resulting from mitochondrial dysfunction and accumulation of organic acids [146].
  • Acute kidney injury (AKI), caused by inhibition of renal vasodilatory prostaglandins, leading to reduced glomerular filtration rate and acute tubular necrosis [147].
  • Electrolyte imbalances, such as hypokalemia and hyponatremia, often secondary to renal dysfunction and gastrointestinal losses [148].
  • Progressive CNS depression, potentially leading to coma, requiring endotracheal intubation and mechanical ventilation in severe cases [148].

In massive overdoses, seizures and cardiac arrhythmias may occur, though less commonly than with other drug classes [7].

Immediate Management in the Emergency Setting

The management of ibuprofen overdose is primarily supportive, as there is no specific antidote. The focus is on decontamination, hemodynamic support, and prevention of organ damage.

Gastrointestinal Decontamination

  • Activated charcoal is recommended if administered within 1–2 hours of ingestion, as it adsorbs ibuprofen in the gastrointestinal tract and reduces systemic absorption [7]. It is particularly effective in significant ingestions.
  • Gastric lavage is not routinely recommended but may be considered in cases of massive ingestion with early presentation, provided airway protection is ensured [7].

Supportive and Specific Treatments

  • Intravenous fluid resuscitation is crucial to maintain renal perfusion and prevent acute kidney injury, especially in patients with hypovolemia or dehydration [7].
  • Continuous monitoring of vital signs, renal function (urea, creatinine, electrolytes), acid-base balance, and liver enzymes is essential for early detection of organ dysfunction [7].
  • Respiratory support may be required in cases of severe CNS depression, including intubation and mechanical ventilation [155].
  • Urinary alkalinization with sodium bicarbonate may be considered in severe cases to enhance renal excretion of ibuprofen, an acidic drug, by increasing its ionization [156].
  • Gastroprotection with proton pump inhibitors (PPIs) or antacids is advised in patients with gastrointestinal symptoms to prevent ulceration and bleeding [7].
  • Hemodialysis may be necessary in cases of refractory acute kidney injury or severe metabolic disturbances, although ibuprofen’s high protein binding limits dialytic clearance [158].

Special Considerations in Vulnerable Populations

Children

Children, particularly those under 6 years, are at high risk for accidental overdose due to the palatable taste of liquid formulations. A toxic dose is considered greater than 400 mg/kg, though adverse effects can occur at lower levels, especially in infants [159]. Diagnosis relies on history, clinical presentation, and laboratory tests including renal and hepatic function panels. Management includes activated charcoal (if within 1–2 hours), supportive care, and monitoring for seizures or CNS depression [160]. Hospitalization is recommended for symptomatic children or those with massive ingestions.

Elderly Patients

The elderly are more susceptible to ibuprofen toxicity even at therapeutic doses due to age-related declines in renal function and hepatic metabolism, as well as frequent use of concomitant medications such as diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) [161]. Overdose in this group can rapidly lead to acute kidney injury, gastrointestinal hemorrhage, and cardiovascular complications such as heart failure exacerbation [29]. Treatment involves immediate discontinuation, cautious fluid resuscitation to avoid volume overload, and renal and gastrointestinal support.

Differentiation from Other NSAID Overdoses

While ibuprofen overdose shares common features with other NSAID intoxications—such as gastrointestinal, renal, and neurological effects—it is distinguished by a more prominent risk of CNS depression, likely due to its lipophilicity and ability to cross the blood-brain barrier [163]. Compared to other NSAIDs like diclofenac, ibuprofen is considered to have moderate gastrointestinal toxicity but a higher risk of CNS effects in overdose [164]. Cardiovascular risk is significant at high doses (≥2400 mg/day), with increased incidence of myocardial infarction and cardiac arrest [77]. Unlike acetaminophen overdose, there is no specific antidote like acetylcysteine, making supportive care the cornerstone of management [166].

Prevention and Public Health Implications

Preventing overdose involves public education on proper dosing, secure storage away from children, and awareness of risks associated with prolonged or high-dose use. Regulatory agencies like ANVISA in Brazil and INFARMED in Portugal enforce strict labeling requirements, including warnings about gastrointestinal, cardiovascular, and renal risks, and mandate pharmacist counseling for over-the-counter sales [167]. Continuous post-marketing surveillance through pharmacovigilance systems helps detect emerging safety concerns and update clinical guidelines accordingly.

References